GO
| HSI1 | 25,884.43 | +25.55 | 328.18B |
| HSCEI1 | 8,612.15 | -32.56 | 103.63B |
| Back Zoom + Zoom - Block Traded | |
|
2026-07-31 16:22:57 UBS published a research report on HUTCHMED (00013.HK), of which revenue for 1H inched up 0.2% YoY, broadly in line with the broker's expectations. Revenue from the oncology or immunology business elevated 13% YoY, above the broker's forecast. Net profit was USD15.9 million, compared with USD455 million in the same period last year, owing to a one-off gain recognized from the disposal of the joint venture, Shanghai Pharmaceuticals, in the same period last year. The broker deferred AstraZeneca milestone payments to 2027 and revised its expense forecasts, leading to a downward revision in 2026 EPS forecasts, while its 2027 forecast was raised from USD0.06 to USD0.08. The broker lowered the company's TP from HKD29.7 to HKD29.5 and reiterated the Buy rating. ~ AASTOCKS Financial News Website: www.aastocks.com | |